Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 191

1.

Mitoxantrone for multiple sclerosis.

Martinelli Boneschi F, Vacchi L, Rovaris M, Capra R, Comi G.

Cochrane Database Syst Rev. 2013 May 31;(5):CD002127. doi: 10.1002/14651858.CD002127.pub3. Review.

2.

Neutralizing antibodies explain the poor clinical response to interferon beta in a small proportion of patients with multiple sclerosis: a retrospective study.

Sbardella E, Tomassini V, Gasperini C, Bellomi F, Cefaro LA, Morra VB, Antonelli G, Pozzilli C.

BMC Neurol. 2009 Oct 13;9:54. doi: 10.1186/1471-2377-9-54.

3.

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.

Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung HP, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr KM, Ravnborg M, Rieckmann P, Wynn D, Young C, Filippi M; PreCISe study group.

Lancet. 2009 Oct 31;374(9700):1503-11. doi: 10.1016/S0140-6736(09)61259-9. Epub 2009 Oct 6. Erratum in: Lancet. 2010 Apr 24;375(9724):1436.

PMID:
19815268
4.

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.

Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Radü EW, Metzig C, Bauer L, Lanius V, Sandbrink R, Pohl C; BENEFIT Study Group.

Lancet Neurol. 2009 Nov;8(11):987-97. doi: 10.1016/S1474-4422(09)70237-6. Epub 2009 Sep 10.

PMID:
19748319
5.

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.

O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung HP, Jeffery D, Kappos L, Boateng F, Filippov V, Groth M, Knappertz V, Kraus C, Sandbrink R, Pohl C, Bogumil T; BEYOND Study Group, O'Connor P, Filippi M, Arnason B, Cook S, Goodin D, Hartung HP, Kappos L, Jeffery D, Comi G.

Lancet Neurol. 2009 Oct;8(10):889-97. doi: 10.1016/S1474-4422(09)70226-1. Epub 2009 Sep 2. Erratum in: Lancet Neurol. 2011 Feb;10(2):115. Lancet Neurol. 2009 Nov;8(11):981. Lancet Neurol. 2012 Jan;11(1):27. Cree, B [added]; Harung, H-P [corrected to Hartung, H-P].

PMID:
19729344
6.

Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study.

Weber-Schoendorfer C, Schaefer C.

Mult Scler. 2009 Sep;15(9):1037-42. doi: 10.1177/1352458509106543.

PMID:
19692433
7.

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D.

Ann Intern Med. 2009 Aug 18;151(4):W65-94. Epub 2009 Jul 20.

PMID:
19622512
8.

Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.

Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Zimatore GB, Tortorella C, Simone IL, Patti F, Ghezzi A, Portaccio E, Rossi P, Pozzilli C, Salemi G, Lugaresi A, Bergamaschi R, Millefiorini E, Clerico M, Lus G, Vianello M, Avolio C, Cavalla P, Iaffaldano P, Direnzo V, D'Onghia M, Lepore V, Livrea P, Comi G, Amato MP; Italian Multiple Sclerosis Database Network Group.

J Neurol Sci. 2009 Nov 15;286(1-2):109-13. doi: 10.1016/j.jns.2009.06.036. Epub 2009 Jul 16.

PMID:
19615696
9.

AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions--agency for healthcare research and quality and the effective health-care program.

Owens DK, Lohr KN, Atkins D, Treadwell JR, Reston JT, Bass EB, Chang S, Helfand M.

J Clin Epidemiol. 2010 May;63(5):513-23. doi: 10.1016/j.jclinepi.2009.03.009.

PMID:
19595577
10.

Antibodies against interferon-beta in multiple sclerosis.

Aarskog NK, Marøy T, Myhr KM, Vedeler CA.

J Neuroimmunol. 2009 Jul 25;212(1-2):148-50. doi: 10.1016/j.jneuroim.2009.04.012. Epub 2009 May 20.

PMID:
19467718
11.

Glatiramer acetate treatment in PPMS: why males appear to respond favorably.

Wolinsky JS, Shochat T, Weiss S, Ladkani D; PROMiSe Trial Study Group.

J Neurol Sci. 2009 Nov 15;286(1-2):92-8. doi: 10.1016/j.jns.2009.04.019. Epub 2009 May 8.

PMID:
19426995
12.

Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study.

Oturai AB, Koch-Henriksen N, Petersen T, Jensen PE, Sellebjerg F, Sorensen PS.

Eur J Neurol. 2009 Mar;16(3):420-3. doi: 10.1111/j.1468-1331.2008.02517.x.

PMID:
19364368
13.

The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.

Koch-Henriksen N, Sorensen PS, Bendtzen K, Flachs EM.

Mult Scler. 2009 May;15(5):601-5. doi: 10.1177/1352458508101946. Epub 2009 Mar 19.

PMID:
19299439
14.

Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.

Cadavid D, Wolansky LJ, Skurnick J, Lincoln J, Cheriyan J, Szczepanowski K, Kamin SS, Pachner AR, Halper J, Cook SD.

Neurology. 2009 Jun 9;72(23):1976-83. doi: 10.1212/01.wnl.0000345970.73354.17. Epub 2009 Mar 11.

PMID:
19279320
15.

Neutralizing antibodies in multiple sclerosis patients treated with 375 micrograms interferon-beta-1b.

Durelli L, Barbero P, Cucci A, Ferrero B, Ricci A, Contessa G, De Mercanti S, Ripellino P, Lapuma D, Viglietta E, Bergui M, Versino E, Clerico M; OPTIMS Trial NAb Sub-Study Group.

Expert Opin Biol Ther. 2009 Apr;9(4):387-97. doi: 10.1517/14712590902762781 .

PMID:
19278300
16.

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.

Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, O'Connor PW, Giovannoni G, Phillips JT, Lublin FD, Pace A, Kim R, Hyde R.

Lancet Neurol. 2009 Mar;8(3):254-60. doi: 10.1016/S1474-4422(09)70021-3. Epub 2009 Feb 7.

PMID:
19201654
17.

Interferon beta for primary progressive multiple sclerosis.

Rojas JI, Romano M, Ciapponi A, Patrucco L, Cristiano E.

Cochrane Database Syst Rev. 2009 Jan 21;(1):CD006643. doi: 10.1002/14651858.CD006643.pub2. Review. Update in: Cochrane Database Syst Rev. 2010;(1):CD006643.

PMID:
19160292
18.

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

CAMMS223 Trial Investigators, Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, Norris K, Tandon PK.

N Engl J Med. 2008 Oct 23;359(17):1786-801. doi: 10.1056/NEJMoa0802670.

19.

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.

Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, Stubinski B, Uitdehaag B; REGARD study group.

Lancet Neurol. 2008 Oct;7(10):903-14. doi: 10.1016/S1474-4422(08)70200-X. Epub 2008 Sep 11.

PMID:
18789766
20.

Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results.

Giovannoni G, Barbarash O, Casset-Semanaz F, King J, Metz L, Pardo G, Simsarian J, Sørensen PS, Stubinski B; Rebif New Formulation Study Group.

Mult Scler. 2009 Feb;15(2):219-28. doi: 10.1177/1352458508097299. Epub 2008 Aug 28.

PMID:
18755819

Supplemental Content

Support Center